Swim Across America Grant Funding of Memorial Sloan-Kettering Cancer Center Clinical Trial Shows that Immunotherapy Alone Could Replace Surgery, Enabling Patients to Retain Their Organs and Enhance Their Quality of Life

Posted on April 27, 2025July 10, 2025 Posted in #DefeatCancer, #MakingWavesToFightCancer, #SwimAcrossAmerica, AACR, beneficiaries, Events, Fundraising, Grant, Long Island Sound, Making Waves With Hope, Messages of Hope, Nassau/Suffolk - Sound to Cove, NewsTagged cancer, cancer research, health, immune-system, immunotherapy, media, medicine, News, swim across americaLeave a comment

The Promising Study Found that 80% of Patients with Mismatch Repair-Deficient (MMRd) Solid Tumors Treated with Immunotherapy Avoided Surgery

The New England Journal of Medicine published a paper on April 27, 2025, that presents exciting new results from a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) gastrointestinal oncologists Andrea Cercek, MD, and Luis Diaz Jr., MD, that demonstrates how immunotherapy alone can help patients with MMRd cancers avoid surgery and preserve their quality of life. The results, presented simultaneously at the 2025 American Association of Cancer Research (AACR) Annual Meeting, showed that 80% of patients with several types of cancer treated with immunotherapy did not require surgery, radiation, or chemotherapy after six months of treatment with immunotherapy alone. Swim Across America awarded grants for the early-stage research and continues to award grants for the ongoing clinical trial.

*Andrea Cercek, M.D., gastrointestinal oncologist and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer at Memorial Sloan Kettering Cancer Center*

Mismatch repair deficiency (MMRd) in cancer refers to a situation where tumor cells have defective mismatch repair (MMR) proteins, essential for correcting DNA errors during cell replication. This deficiency leads to the accumulation of mutations, including microsatellite instability (MSI), making tumors more prone to be recognized by the immune system. MMRd status is a significant factor in cancer treatment, particularly for immunotherapy, as it can predict response to immune checkpoint inhibitors.

The standard of care for many cancers that have this specific MMRd genetic mutation has been surgery, radiation, and chemotherapy. Still, the patients who responded positively to this clinical trial did not require surgery to remove an organ and did not experience chemotherapy or radiation, which improved their quality of life. This trial is the first time that immunotherapy has been shown to replace surgery for a variety of solid tumors.

“This study shows that immunotherapy can replace surgery, radiation and chemotherapy for mismatch repair-deficient solid tumors, which could help patients preserve their organs and avoid the harsh side effects of chemo and radiation,” said Andrea Cercek, M.D., gastrointestinal oncologist and co-director of the Center for Young Onset Colorectal and Gastrointestinal Cancer at Memorial Sloan Kettering Cancer Center. “Preserving a patient’s quality of life, while also successfully achieving positive results in eliminating their cancer, is the best possible outcome. They can return to their daily routines and maintain their independence.”

*Luis Diaz, M.D., gastrointestinal oncologist and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center*

This phase 2 trial is an extension of a groundbreaking study, also funded in part by Swim Across America, in which all rectal cancer patients treated with the immunotherapy dostarlimab experienced a complete clinical response, meaning their tumors disappeared. This was the first time ever that a clinical trial had a 100% positive response rate.

The updated trial included 103 patients with stage 1-3 cancer; 49 with rectal cancer; and 54 with non-rectal cancers, including gastroesophageal, hepatobiliary, colon, genitourinary, and gynecologic. Drs. Cercek and Diaz noted that the 80% response rate in this expanded clinical trial is very exciting for these types of cancer.

“Grants provided by Swim Across America were critical to our initial study and advancing this trial to phase 2,” said Luis Diaz, M.D., gastrointestinal oncologist and Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center.

Founded in 1987, Swim Across America has raised more than $100 million to fight cancer. In its 38 years of making waves, thousands of volunteers and Olympians have swum the circumference of the earth three times uniting a movement to fight cancer that has created a groundswell of support spanning all generations. Today, more than 24 communities across the U.S. hold charity swims each year, which support innovative cancer research, detection, and patient programs.

*Drs. Andrea Cercek and Luis Diaz spoke at the 2024 Swim Across America – Long Island Sound open water swim*

Swim Across America’s funding of clinical trials on a national level has helped contribute to four FDA-approved life-saving immunotherapy cancer treatments: Yervoy, Opdivo, Tecentriq, and Keytruda. Swim Across America awards grant to more than 60 projects each year and there are ten named Swim Across America Labs at major institutions.

In addition to Swim Across America grants, this trial received funding from the National Institutes of Health, National Cancer Institute, Haystack Oncology, and Stand Up To Cancer. MSK also acknowledges support from GSK, whose PD-1 blockade Jemperli (dostarlimab), represents a promising advancement in the treatment of patients.

For more information and to inquire about eligibility for this clinical trial, talk to your oncologist or call MSK at 646-888-4189. You may also reach to info@swimacrossamerica.org and we will help guide you.

Swim Across America Presentation and Lab Visit with researcher, Bryan Choi MD, PhD

Posted on April 25, 2025April 25, 2025 Posted in #DefeatCancer, #MakingWavesToFightCancer, #SwimAcrossAmerica, beneficiaries, boston, event directors, Events, Grant, Labs, Making Waves With Hope, Messages of Hope, nantucketTagged biology, cancer, cancer research, health, immunotherapy, medicine, News, swim across americaLeave a comment

Choi’s next generation CAR-T therapy, funded in part by SAA-Boston and SAA-Nantucket, has shown “dramatic and rapid” regression of glioblastoma

With early funding from Swim Across America – Boston and Swim Across America – Nantucket, Dr. Bryan Choi’s research on tandem CAR T-cell therapy for ependymoma was approved for a Phase I trial. The first human patient was infused at the end of April 2023. The results of the first human trials, as described in 2024 by the New England Journal of Medicine, showed “dramatic and rapid” regression of glioblastoma.

In an exclusive briefing to Swim Across America participants, Dr. Bryan Choi, a neurosurgeon and neuro-oncologist at Massachusetts General Cancer Center, delivered an update on his research path.

*From left, brain tumors, marked by red and green arrows, disappear a day after CAR-T immunotherapy treatment. From CNN.*

The Swim Across America lab visit included not only highlights from on the ongoing Phase I trial, but also a few first-hand stories about the life-changing impacts of the new CAR-T cell therapy for one of the patients, who has chosen to share his story publicly.

Tom Fraser (Patient #2) has shared his story publicly with news outlets that include CNN and New York Magazine.

Tom Fraser, 72, (center, in the blue shirt) was treated with a single infusion of CAR-T cells. Two days later, an MRI showed a decrease in the tumor’s size by 18.5 percent. By day 69, the tumor had decreased by 60.7 percent, and the response was sustained for over 6 months. From The Harvard Gazette.

CAR T-cell therapy, a type of gene therapy that engineers a patient’s own T-cells (a type of white blood cells) to identify and attack cancer cells by way of their antigen markers, has shown promise in the treatment of blood cancers. The research team created dual antigen-targeting tandem CAR T (TanCART) cells to target heterogeneous solid tumors. Dr. Choi’s research shows that this type of therapy can also be manipulated to treat solid tumors like ependymoma.

At the suggestion of Dr. Howard Weinstein, Unit Chief of Pediatric Hematology/Oncology at Mass General for Children and long-time Swim Across America partner, Dr. Choi applied for a Swim Across America research grant through the internal competitive bid program at Mass General for Children.

*Dr. Choi recruiting the next generation of researchers, like SAA – Nantucket supporter, Braden Hussey.*

Without the Swim Across America grant, Dr. Choi said, his research likely would have remained unfunded, and neither the FDA approval nor the Phase I Study approval, which is funded by industry investors, would have been possible.

Janel Jorgensen McArdle, Chief Operating Officer of Swim Across America, pointed out that Dr. Choi’s research falls in the “sweet spot” of the high risk, high reward research that Swim Across America is pursuing.

“This promising research aligned perfectly with the opportunities that Swim Across America seeks to support,” said McArdle. “We are so excited that SAA funding could help accelerate it to patient trials – and are thrilled to see the benefits to patients!”

*Dr. Choi explained CAR-T cell therapy to the Swim Across America group on April 4, 2025.*

After his highly informative presentation, Dr. Choi gave the Swim Across America group a private tour of his lab spaces, which were in the finishing stages of build-out when they toured two years ago.

The group also got to visit the Ether Dome at Mass General, the surgical amphitheater where, in 1846, the first public surgery with anesthesia was performed.

It was an exciting visit for Swim Across America news and for all of the Swim Across America – Boston and Nantucket supporters who were present!

*Swim Across America lab visit participants, pictured with Dr. Choi in the Ether Dome at Mass General, site of the first use of anesthesia in public surgery.*

Swim Across America – Seattle Shares 2024 Impact Report and Progress Updates

Posted on February 13, 2025February 13, 2025 Posted in #MakingWavesToFightCancer, #SwimAcrossAmerica, beneficiaries, seattle, UncategorizedTagged biology, cancer, fundraise, fundraising, health, immunotherapy, medicine, Philanthropy, swim across america, swimmingLeave a comment

For 15 years, Swim Across America has fueled innovative early-stage research at Fred Hutch Cancer Center and UW Medicine and helped launch the careers of dozens of young scientists. We’re proud to share details about the six most recent projects made possible through funds raised in 2022 and 2023 by Swim Across America – Seattle and the dedicated swimmers who participated. From improving patients’ quality of life to overcoming tumors’ resistance to immunotherapy, these innovative projects have the potential to dramatically enhance cancer treatment.

Inspired to Make Waves to Fight Cancer this year? Swim, volunteer or donate to SAA-Seattle at swimacrossamerica.org/seattle.

Kate Markey, MBBS, PhD, FRACP | Stem cell transplantation

Assistant Professor, Fred Hutch and UW Medicine

Project: Restoring the gut microbiome after blood stem cell transplant

Background: Fred Hutch researchers have shown that while blood stem cell transplantation continues to be the most effective treatment for multiple myeloma, it can also severely damage patients’ gut microbiome, leading to strong gastrointestinal side effects and poor outcomes. Dr. Markey, a medical oncologist who studies the gut microbiome and its role in recovery from transplant, developed a study to examine whether a five-week, plant based, whole-food diet can restore patients’ beneficial gut bacteria and improve immune function and outcomes.

2024 progress statement: Dr. Markey and her colleagues opened the trial in October, and by the end of the following month they had enrolled seven patients, or one-third of their goal. They are collecting stool and blood samples and plan to analyze all of them once the trial is complete. If all goes as expected this summer they intend to use the resulting data to apply for a federal research grant to support a much larger, randomized clinical trial.

Alexandre Hirayama, MD | Blood cancers

Assistant Professor, Fred Hutch and UW Medicine

Project: Understanding how large B-cell lymphoma evades CAR T-cell therapy

Background: Less than half of patients who undergo CAR T-cell therapy for large B-cell lymphoma (LBCL) enjoy long-lasting remission. We’re not sure why, but the answer may lie in the tumor microenvironment. There’s still so much we don’t know about this collection of cells, stroma, and blood vessels that surround and support the tumor, including how it might suppress cancer therapies. Dr. Hirayama, who specializes in treating patients with B-cell malignancies, is studying the tumor microenvironment in minute detail to help identify and explain how patients’ tumors may mute CAR T cells’ effectiveness.

2024 progress statement: Dr. Hirayama has gathered the necessary tumor samples for these studies and refined the techniques and technologies that will allow him to study immune, stromal, and tumor cells in the tumor microenvironment. He expects to begin studying the samples in summer 2025.

Diane Tseng, MD, PhD | Lung cancer

Assistant Professor, Fred Hutch and UW Medicine

Project: Reducing inflammatory effects of immunotherapy in patients with lung cancer

Background: Many patients with lung cancer who are treated with checkpoint inhibitors experience a condition called checkpoint inhibitor pneumonitis (CIP). If left untreated, CIP can cause irreversible damage. Recent research shows that immune cells called napsin A–specific T cells may be involved in mediating CIP. Dr. Tseng, an oncologist who specializes in treating patients with lung cancer, is working with McGarry Houghton, MD — a Fred Hutch and UW Medicine professor and holder of the Satya and Rao Remala Family Endowed Chair — to study napsin A–specific T cells’ role in CIP and exploring strategies for muting it.

2024 progress statement: Dr. Tseng’s work has focused on 1) developing a method for detecting napsin A– specific T cells in donor blood; 2) developing a method for taking those cells and growing more of them in the lab; and 3) creating a test to determine whether a different T cell can eliminate them. This work will establish the foundations for understanding the function of napsin A–specific T cells and the role they might play in CIP.

Emily Liang, MD | Blood cancers

Hematology/oncology Fellow, Fred Hutch and UW Medicine

Project: Mitigating serious side effects of CAR T-cell therapies in patients with blood cancers

Background: While CAR T-cell therapy has revolutionized treatment for patients with blood cancers like lymphoma and multiple myeloma, it also comes with a high risk of fever, fatigue, body aches, and even neurologic impairment. Though these conditions are reversible, they can be life-threatening and prevent older and frailer patients from receiving CAR T-cell therapy at all. Dr. Liang, who specializes in acute leukemias and CAR T-cell therapy, and her mentor, Jordan Gauthier, MD, MSC, a Fred Hutch and UW professor and former Swim Across America funding recipient, want to make these treatments accessible to a wider range of patients. So, the pair launched a first of-its-kind trial to study whether a drug typically prescribed for rheumatoid arthritis called anakinra can prevent these inflammatory responses.

2024 progress statement: After treating more than 30 patients in their clinical trial, Drs. Liang and Gauthier found that prophylactic administration of anakinra did not seem to be effective in preventing cytokine release syndrome, a side effect associated with a high level of inflammation in the blood. However, prophylactic anakinra did seem to reduce the severity and duration of neurologic side effects as well as the need for steroids. Importantly, Drs. Liang and Gauthier also found that anakinra may impair the treatment’s effectiveness against tumors. Now, the pair are planning to study how anakinra mitigates inflammation in the brain, whether there may be alternative prevention strategies, and how anakinra impacts CAR T-cell function.

Saurav Kumar, PhD | Colorectal cancer

Postdoctoral Fellow, Fred Hutch

Project: Exploring new uses for existing drugs to treat colorectal cancer

Background: Colorectal cancer is one of several cancers driven by a process called gene fusion, in which two independent genes combine incorrectly and begin producing proteins that can lead to cancer. And though a range of drugs have been developed to target these fusions and stop the mechanism that promotes cancer growth, they’ve so far been ineffective against colorectal cancer. However, Dr. Kumar, who studies metastasis, recently discovered that patients with colon cancer who receive TRK inhibitors (TRKi) experience a drop in TRK fusion protein levels, suggesting that these inhibitors may be degrading the cancer-causing fusion proteins. He plans to study the interaction that causes this protein degradation with the goal of one day using TRKi to create more effective therapies for patients with this form of cancer.

2024 progress update: Dr. Kumar and his colleagues have developed three protein degraders, called PROTACs, based on an FDA-approved TRKi. Now they plan to begin testing them on colorectal cancer cells in the lab to better understand the mechanism that leads to TRK fusion protein degradation — which could one day inform the development of targeted therapies for patients with these cancers.

Yapeng Su, PhD | Pancreatic cancer

Postdoctoral Fellow, Fred Hutch

Project: Overcoming solid tumors’ resistance to immunotherapies

Background: Pancreatic cancer is notoriously difficult to treat. Though we’ve found a protein on tumor cells that would seemingly make for a good immunotherapy target, treatments that have been studied and validated in the lab fail in patients — likely due to unique characteristics of the tumor microenvironment. Using technology that allows us to see the interaction of cells within tumors and better understand how they influence one another, Dr. Su, who studies adoptive cellular immunotherapy, is examining the mechanisms that cause immunotherapies to fail and exploring techniques to overcome them.

2024 progress statement: After completing a detailed study of samples from tumors previously treated with adoptive T cell therapy, Dr. Su found that they contained several cell types that were both potentially immunosuppressive and arranged in distinct patterns throughout the tumor microenvironment. He also identified several subtypes of T cells (whose role is to attack cancer cells) that no longer functioned properly. In the coming months, Dr. Su plans to further analyze the T-cell subtypes and their placement within the tumor microenvironment to better understand why they stop working. What he finds could one day help us better engineer T cells to overcome those immunosuppressive forces.